当前位置:
X-MOL 学术
›
Lipids Health Dis.
›
论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Apolipoprotein CIII predicts cardiovascular events in patients with coronary artery disease: a prospective observational study.
Lipids in Health and Disease ( IF 4.5 ) Pub Date : 2020-05-30 , DOI: 10.1186/s12944-020-01293-9 Julius L Katzmann 1 , Christian M Werner 2 , Tatjana Stojakovic 3 , Winfried März 4, 5, 6 , Hubert Scharnagl 4 , Ulrich Laufs 1
Lipids in Health and Disease ( IF 4.5 ) Pub Date : 2020-05-30 , DOI: 10.1186/s12944-020-01293-9 Julius L Katzmann 1 , Christian M Werner 2 , Tatjana Stojakovic 3 , Winfried März 4, 5, 6 , Hubert Scharnagl 4 , Ulrich Laufs 1
Affiliation
Apolipoprotein CIII (apoCIII) is associated with triglyceride-rich lipoprotein metabolism and has emerged as independent marker for risk of cardiovascular disease. The objective was to test whether apoCIII is regulated postprandially and whether apoCIII concentrations in native and chylomicron-free serum predict future cardiovascular events in patients with stable coronary artery disease (CAD). ApoCIII concentrations were measured in native and chylomicron-free serum in the fasting state and after a standardized oral fat load test in 195 patients with stable CAD. Clinical follow-up was 48 months. Chylomicron-free serum was prepared by ultracentrifugation (18,000 rpm, 3 h). The log-rank test and Cox regression analyses were used to investigate the association of apoCIII with recurrent cardiovascular events. Of the 195 patients included, 92 had a cardiovascular event, and 103 did not. 97% were treated with a statin. No significant changes in apoCIII concentration were observed after the oral fat load test. The apoCIII concentration was associated with event-free survival independent of conventional risk factors. This association reached statistical significance only for apoCIII concentration measured in chylomicron-free serum (hazard ratio [95% confidence interval] for apoCIII above the mean: postprandial: 1.67 (1.06–2.29), P = 0.028, fasting: 2.09 (1.32–3.32), P = 0.002), but not for apoCIII concentration measured in native serum (postprandial: 1.47 [0.89–2.43], P = 0.133, fasting: 1.56 [0.95–2.58], P = 0.081). The effects were independent of other risk factors. ApoCIII concentrations in chylomicron-free serum are independently associated with event-free survival in patients with CAD both in fasting and postprandial state. This findings support considering apoCIII for risk assessment and attempting to test the hypothesis that lowering apoCIII reduces residual cardiovascular risk. Apolipoprotein CIII concentration measured in chylomicron-free serum predicts recurrent cardiovascular events in patients with stable coronary artery disease. The trial which included the participants of this study was registered at https://clinicaltrials.gov (NCT00628524) on March 5, 2008.
中文翻译:
载脂蛋白CIII可以预测冠心病患者的心血管事件:一项前瞻性观察性研究。
载脂蛋白CIII(apoCIII)与富含甘油三酸酯的脂蛋白代谢有关,并已成为心血管疾病风险的独立标记。目的是测试餐后是否对apoCIII进行调节,以及天然和不含乳糜微粒的血清中apoCIII的浓度是否可预测稳定冠心病(CAD)患者的未来心血管事件。在禁食状态下对自然和不含乳糜微粒的血清中ApoCIII的浓度进行了测定,并在195名稳定CAD的患者中进行了标准化的口服脂肪负荷测试。临床随访48个月。通过超速离心(18,000 rpm,3 h)制备不含乳糜微粒的血清。使用对数秩检验和Cox回归分析来研究apoCIII与复发性心血管事件的关系。在195名患者中,92人有心血管事件,而103人没有。97%的患者接受了他汀类药物治疗。口服脂肪负荷试验后,apoCIII浓度未见明显变化。apoCIII浓度与无事件生存相关,独立于常规危险因素。这种联系仅在无乳糜微粒血清中测量的apoCIII浓度才达到统计意义(apoCIII的危险比[95%置信区间]高于平均值:餐后:1.67(1.06-2.29),P = 0.028,禁食:2.09(1.32-3.32 ),P = 0.002),但未测量天然血清中的apoCIII浓度(餐后:1.47 [0.89–2.43],P = 0.133,禁食:1.56 [0.95–2.58],P = 0.081)。影响与其他危险因素无关。在空腹和餐后状态下,CAD患者的无乳糜微粒血清中的ApoCIII浓度与无事件生存率独立相关。这一发现支持将apoCIII用于风险评估,并试图检验降低apoCIII可降低残留心血管风险的假设。在不含乳糜微粒的血清中测得的载脂蛋白CIII浓度可预测稳定冠心病患者的复发性心血管事件。包括本研究参加者在内的该试验于2008年3月5日在https://clinicaltrials.gov(NCT00628524)上注册。在不含乳糜微粒的血清中测得的载脂蛋白CIII浓度可预测稳定冠心病患者的复发性心血管事件。包括本研究参加者在内的该试验于2008年3月5日在https://clinicaltrials.gov(NCT00628524)上注册。在不含乳糜微粒的血清中测得的载脂蛋白CIII浓度可预测稳定冠心病患者的复发性心血管事件。包括本研究参与者的试验已于2008年3月5日在https://clinicaltrials.gov(NCT00628524)上注册。
更新日期:2020-05-30
中文翻译:
载脂蛋白CIII可以预测冠心病患者的心血管事件:一项前瞻性观察性研究。
载脂蛋白CIII(apoCIII)与富含甘油三酸酯的脂蛋白代谢有关,并已成为心血管疾病风险的独立标记。目的是测试餐后是否对apoCIII进行调节,以及天然和不含乳糜微粒的血清中apoCIII的浓度是否可预测稳定冠心病(CAD)患者的未来心血管事件。在禁食状态下对自然和不含乳糜微粒的血清中ApoCIII的浓度进行了测定,并在195名稳定CAD的患者中进行了标准化的口服脂肪负荷测试。临床随访48个月。通过超速离心(18,000 rpm,3 h)制备不含乳糜微粒的血清。使用对数秩检验和Cox回归分析来研究apoCIII与复发性心血管事件的关系。在195名患者中,92人有心血管事件,而103人没有。97%的患者接受了他汀类药物治疗。口服脂肪负荷试验后,apoCIII浓度未见明显变化。apoCIII浓度与无事件生存相关,独立于常规危险因素。这种联系仅在无乳糜微粒血清中测量的apoCIII浓度才达到统计意义(apoCIII的危险比[95%置信区间]高于平均值:餐后:1.67(1.06-2.29),P = 0.028,禁食:2.09(1.32-3.32 ),P = 0.002),但未测量天然血清中的apoCIII浓度(餐后:1.47 [0.89–2.43],P = 0.133,禁食:1.56 [0.95–2.58],P = 0.081)。影响与其他危险因素无关。在空腹和餐后状态下,CAD患者的无乳糜微粒血清中的ApoCIII浓度与无事件生存率独立相关。这一发现支持将apoCIII用于风险评估,并试图检验降低apoCIII可降低残留心血管风险的假设。在不含乳糜微粒的血清中测得的载脂蛋白CIII浓度可预测稳定冠心病患者的复发性心血管事件。包括本研究参加者在内的该试验于2008年3月5日在https://clinicaltrials.gov(NCT00628524)上注册。在不含乳糜微粒的血清中测得的载脂蛋白CIII浓度可预测稳定冠心病患者的复发性心血管事件。包括本研究参加者在内的该试验于2008年3月5日在https://clinicaltrials.gov(NCT00628524)上注册。在不含乳糜微粒的血清中测得的载脂蛋白CIII浓度可预测稳定冠心病患者的复发性心血管事件。包括本研究参与者的试验已于2008年3月5日在https://clinicaltrials.gov(NCT00628524)上注册。